Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Captisol-Enabled Budesonide vs Rhinocort Aqua in SAR
NCT00938613Phase 2Completed
- Sponsor
- Ligand Pharmaceuticals
- Start
- Feb 2007
- Primary completion
- Apr 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EPI-EE in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Ligand Pharmaceuticals. Primary endpoint: Total Nasal Symptom Score. Started Feb 2007; status: completed.
02
Drugs
EPI-EE
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00938613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00938613.